Next week, our CEO, Faraz Ali, will participate in a fireside chat at the Canaccord Genuity Growth Conference. Read our press release for more details: bit.ly/41yemgu #TenayaTherapeutics #GeneTherapy #CanaccordGenuity

Tenaya is hosting an expert in the development of mass spectrometry-based proteomic techniques to discuss "Measuring Protein Expression in Cardiac Gene Therapy." The event will be broadcast live and available on the Tenaya website. Register below bit.ly/3JyBSnO

Dr. Georgia Sarquella Brugada will present interim results from MyClimb, our natural history study of pediatric MYBPC3-associated #HCM at European Society of Cardiology Congress in Madrid taking place from August 29 to September 1. #ESCCongress2025 #GeneTherapy

Today, we presented interim data from MyClimb™ at European Society of Cardiology Congress in Madrid. With more than 200 participants, it is the largest noninterventional natural history study of people under 18 with MYBPC3-associated HCM. Learn more in our press release: bit.ly/3JyRrMf

Next week, our CEO, Faraz Ali, will participate in a fireside chat at the Morgan Stanley Annual Global Healthcare Conference. bit.ly/45TdbJW #TenayaTherapeutics #GeneTherapy

Last week #TeamTenaya gathered for our company picnic — soaking up the last bit of summer and enjoying time together outside the office.

#TeamTenaya is still energized from presenting interim results from our MyClimb™ study at #ESCCongress2025. Thank you, Dr. Georgia Sarquella Brugada and the HCM community, without your support, this work would not be possible. #GeneTherapy #HeartDisease

We’ve launched our HCP Resource Center—a new section of our website for healthcare professionals (HCPs) interested in learning more about gene therapy for heart disease. Learn how genetic insights are shaping the future of care. Explore here: bit.ly/3HWDW8G #HeartHealth

Did you miss our recent webinar? If so, you can learn more about the challenges of measurement in haploinsufficient settings and the rigorous methodology of #TeamTenaya to measure proteins. Tune in ahead of our planned Phase 1 data readouts in Q4. bit.ly/3JyBSnO

This #WorldHeartDay, we echo World Heart Federation’s theme: “Don’t Miss a Beat.” Every day, we are researching rare heart diseases like #HCM and #ARVC and advancing genetic medicines targeting the root causes of these conditions.

Next week, our CEO Faraz Ali will participate in #CGMesa25 presented by the Alliance for Regenerative Medicine (ARM). Faraz will join a panel on emerging trends in cell and gene therapy and deliver a company presentation highlighting our gene therapy programs focused on heart disease.

Tenaya will be participating in two upcoming investor and industry conferences this month. Read the press release to learn more: bit.ly/3ITENXY

#TeamTenaya joined the American Heart Association 2025 Bay Area CA Heart Walk, raising $3K+ for heart research and education. Guided by the AHA’s slogan “We Walk to Save Lives,” every step and dollar supports CPR training, research, and improving heart health for everyone.

As we prepare to release initial data from our RIDGE-1 Phase 1b clinical trial of TN-401 for PKP2-associated ARVC later this quarter, our team is presenting the clinical trial design and methods for measuring changes in protein levels at ESGCT. #ARVC #GeneTherapy

Visit the FAQ section of Tenaya’s HCP Resource Center for answers on gene therapy and its potential to treat #HCM and #ARVC, including mechanism of action, route of administration details, and more. Explore here: bit.ly/3HWDW8G

Next week, we’ll be participating in the H.C. Wainwright & Co. Genetic Medicines Virtual Conference. We are looking forward to connecting with other leaders in the gene therapy space. Read the press release here: bit.ly/3J339P0

Our CEO, Faraz Ali, will be participating in a panel titled, “In Vivo Gene Therapies for Genetic Cardiac Diseases” on October 21, at Chardan’s 9th Annual Genetic Medicines Conference. If you’re not able to attend, you can tune in via the webcast.

We are looking forward to our late breaking clinical and preclinical presentations at #AHA25 Scientific Sessions presented by Milind Desai MD MBA and Kathy Ivey, Ph.D.! Read the press release for further details here: bit.ly/4hHRS3P

Today, Milind Desai MD MBA shared new interim clinical data on MyPEAK™-1 Phase 1b/2 clinical trial for TN-201 at #AHA25. Missed it? Tune into our webcast on Monday (11/10) at 8 am EST. Details in our press release: bit.ly/4nIOfMg #GeneTherapy #HeartDisease

We reported third quarter financial results and provided business and program updates. Read more: bit.ly/3Lx9dQP #TenayaTherapeutics #GeneTherapy #HeartDisease